[Long-term results of multimodality therapy of XXXX ].

@entity1 @entity2969 @entity2971 @entity4797
OBJECTIVE: To study the clinical characteristics, outcome, prognostic factors and survival of @entity1 with @entity2969 ( @entity2969 ). METHODS: 107 @entity2969 @entity1 received chemotherapy after orchiectomy. The median age of the @entity1 was 32 years. 30.8% (33/107) @entity1 had @entity4797 with 14 (42.4%) stage I lesions. Seventy-four @entity1 had non-seminomatous @entity2971 (NSGCTT) with 21 (28.4%) stage I lesions. The response rate was analyzed with chi(2) test. The survival rate was calculated with Kaplan-Meier method and log-rank test. Therapy including chemotherapy, radiation and necessary salvage operation were performed after orchiectomy. RESULTS: Clinical stage and pathological type were the main prognostic factors. The 3-, 5- and 10-year survival rates were 75.8%, 73.5%, 73.5% for all @entity1 , 100%, 96.8%, 96.8% for @entity4797 and 63.5%, 61.7%, 61.7% for NSGCTTs, respectively. Sixty-four @entity1 were evaluable for response. Seventeen (26.6%) @entity1 achieved CR by chemotherapy alone and an additional 8 @entity1 (12.5%) achieved CR by chemotherapy plus salvage operation or radiation. The 5-year survival rates were 91.7% and 26.2% for @entity1 who achieved CR or not. CONCLUSION: The long-term outcome for stage I @entity2971 is excellent. The treatment outcome and survival in @entity1 with metastatic @entity2969 can be greatly improved by adopting multi-modality therapy with combined chemotherapy as the chief means.
